^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pitavastatin

    i
    Other names: NK 104, P 872441, NK-104-PH
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    HMG-CoA reductase inhibitor
    Related drugs:
    Associations

    News

    Trials
    13d
    Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. (PubMed, FASEB J)
    In cervical cancer cisplatin-resistant cell lines (SiHa-DDP and C33a-DDP) constructed from their parental cells, the effects of seven statins (simvastatin, fluvastatin, pitavastatin, lovastatin, atorvastatin, rosuvastatin, and pravastatin) on cell viability in cisplatin-resistant cells and corresponding parental cells were assessed using the CCK-8 assay...In all, simvastatin enhanced cisplatin sensitivity by suppressing the CAV1-mediated PI3K/AKT pathway involvement in the development of cisplatin resistance in cervical cancer cells. These findings reveal a novel mechanism in cervical cancer cells resistant to cisplatin by which simvastatin may serve as a potential adjuvant to improve the therapeutic efficacy of cisplatin-based chemotherapy.
    Journal
    |
    CAV1 (Caveolin 1)
    |
    cisplatin • simvastatin • atorvastatin • lovastatin • pitavastatin
    13d
    A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults. (clinicaltrials.gov)
    P1, N=12, Recruiting, AbbVie
    New P1 trial
    |
    pitavastatin
    24d
    PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) (clinicaltrials.gov)
    P1, N=18, Recruiting, University of California, Irvine
    New P1 trial
    |
    gemcitabine • albumin-bound paclitaxel • pitavastatin
    1m
    PIVOT: Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study (clinicaltrials.gov)
    P=N/A, N=10000, Recruiting, JW Pharmaceutical
    New trial
    |
    pitavastatin
    1m
    TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. (PubMed, Cancer Res)
    Notably, pitavastatin calcium synergized with the ferroptosis inducer RSL3 to enhance ferroptotic activity and suppress HNSCC progression. These findings delineate a TRAPPC4-FOS-TRIM55-GPX4 signaling axis that drives ferroptosis resistance and tumor progression and highlight TRAPPC4 as a promising therapeutic target for ferroptosis-based intervention in HNSCC.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • TRAPPC4 (Trafficking Protein Particle Complex Subunit 4) • TRIM55 (Tripartite Motif Containing 55)
    |
    RSL3 • pitavastatin
    1m
    A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov)
    P1, N=40, Recruiting, Hoffmann-La Roche
    Trial initiation date
    |
    pitavastatin
    2ms
    BP45863: A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin (2025-521921-34-00)
    P1, N=32, Active, not recruiting, Genentech Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    pitavastatin
    2ms
    TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men (clinicaltrials.gov)
    P2, N=150, Recruiting, Lomonosov Moscow State University Medical Research and Educational Center
    New P2 trial
    |
    pitavastatin
    2ms
    A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov)
    P1, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jun 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    pitavastatin
    3ms
    Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia (clinicaltrials.gov)
    P=N/A, N=6927, Completed, JW Pharmaceutical
    New trial
    |
    pitavastatin
    3ms
    Long-term Comparison of Pitavastatin/Ezetimibe and Pitavastatin in Patients With Hypercholesterolemia and Elevated Triglycerides (clinicaltrials.gov)
    P4, N=88, Active, not recruiting, JW Pharmaceutical
    New P4 trial
    |
    pitavastatin
    3ms
    BP45863: A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin (2025-521921-34-00)
    P1, N=32, Recruiting, Genentech Inc.
    New P1 trial
    |
    pitavastatin